Javier de la Rubia
Javier de la Rubia is an expert in Hematology at Hospital Universitari i Politècnic La Fe (Spain). As of October 2026, ScienceLeadR ranks Javier de la Rubia in the top 1% of experts worldwide for Multiple Myeloma, Paraproteinemias and Hemostatic Disorders. Javier de la Rubia has authored 529 publications, the most recent in 2026, and is an investigator in 64 clinical trials, 21 of them ongoing. SLR score: 2,315 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Transplantation - Oncology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Javier de la Rubia is the Head of the Department of Hematology at the University Hospital La Fe in Valencia, Spain. He earned his medical degree, completed his residency, and a fellowship in Hematology at the Clinical Hematology and Bone Marrow Transplant Unit at the University Hospital La Fe. He is responsible for programs involving the management of patients with multiple myeloma.
He is Professor of Hematology at the Universidad Católica in Valencia, Spain.
He is a member of the advisory board of the Spanish Myeloma Group and a member of the European Hematology Association and the International Myeloma Society. His main research area involves the diagnosis and treatment of patients with multiple myeloma and other monoclonal gammopathies. He has published over 225 peer-reviewed journal articles, several book chapters, and more than 600 abstracts at national and international meetings.
Organizations
Career arc: 1987 - 2026
Number : 529
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| CD84 Expression Across Disease Stages and Leukemic Subpopulations in Acute Myeloid Leukemia. PMID 42795003 — cells, bone marrow, blood, leukemia, leukemia, myeloid, acute, immunotherapy, leukemia, myeloid, diagnosis, therapeutics, clone cells, mutation | Cancers (Basel) | 2026 | 0 |
| Donor NKG2A/NKG2C Immunophenotype Influences the GMP-Compliant Manufacturing Potential of NK Cells for Adoptive Immunotherapy. PMID 42738255 — cells, microscopy, electron, scanning transmission, killer cells, natural, phenotype, cytomegalovirus, immunotherapy, immunotherapy, adoptive, transplants, therapeutics | Cancers (Basel) | 2026 | 0 |
| Pharmacodynamics of Caplacizumab in Healthy Volunteers and Phase 2/3 Trial Patients with Immune-mediated Thrombotic Thrombocytopenic Purpura. PMID 42456747 — purpura, thrombotic thrombocytopenic, von willebrand factor, healthy volunteers, thrombosis, blood platelets, purpura, thrombocytopenic, purpura | Thromb Haemost | 2026 | 0 |
| Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies. PMID 42270486 — dexamethasone, lymphoma, immunotherapy, multiple myeloma, therapeutics, thrombocytopenia | Clin Lymphoma Myeloma Leuk | 2026 | 0 |
| Secondary Malignancies after Hematopoietic Stem Cell Transplantation. PMID 42107884 — cells, mortality, microscopy, electron, scanning transmission, incidence, hematopoietic stem cell transplantation, neoplasms, leukemia, stem cells, transplants, cell transplantation, stem cell transplantation, hematopoietic stem cells, transplantation | Transplant Cell Ther | 2026 | 0 |
Clinical Studies 64
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
21 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study to Investigate the Efficacy Safety and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion 10 ) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving BCMA CD3 Directed Bispecific Antibody Therapy 2024-518420-80-00 — cells, cd3 complex, safety, sudden infant death, immunoglobulins, multiple myeloma, b-cell maturation antigen, therapeutics, globulins, b-lymphocytes, infections | Phase 3 | Recruiting | 2026 |
| MagnetisMM 6 A Phase 3 Study of Elranatamab (PF 06863135) Daratumumab Lenalidomide Versus Daratumumab Bortezomib Lenalidomide Dexamethasone in Transplant Ineligible Participants With Newly Diagnosed Multiple Myeloma 2024-514139-50-00 — safety, dexamethasone, bortezomib, multiple myeloma, lenalidomide, transplants | Phase 3 | Recruiting | 2022 |
| A Phase 3 Study Comparing JNJ 79635322 and an anti BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma 2025-522007-18-00 — multiple myeloma, therapeutics | Phase 3 | Recruiting | 2026 |
| Phase 1 2 multicenter open label dose escalation study of IDP 121 in patients with relapsed refractory hematologic malignancies (CASSANDRA) 2024-519194-19-00 — cells, inosine diphosphate, lymphoma, b-cell, hematologic neoplasms, lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, multiple myeloma, b-lymphocytes | Phase 1/Phase 2 | Recruiting | 2023 |
| A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L RRMM Monotherapy Study) 2023-506668-15-00 — multiple myeloma, therapeutics | Phase 3 | Active not recruiting | 2024 |
LeadR Networks
Main global connection map